- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04707131
A Study of Single Ascending Dose of LEM-S401 in Healthy Participants
February 14, 2023 updated by: Lemonex Inc.
A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Phase I Clinical Trial to Evaluate the Characteristics of the Safety, Tolerability and Pharmacokinetics of LEM-S401 in Healthy Adult Subjects
The primary objective of the study is to assess the safety and tolerability of single dose of LEM-S401 in healthy adult subjects.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study is designed to evaluate the safety and tolerability of LEM-S401 administered as subcutaneous injection in healthy adult subjects.
Overall, 18 subjects will be studied in 3 groups. Each subject will receive LEM-S401 or placebo subcutaneously.
Study Type
Interventional
Enrollment (Actual)
19
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Cheongju, Korea, Republic of
- Chungbuk National University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy male and female subjects aged 19 to ≤ 65 years at screening
Exclusion Criteria:
- Significant history or clinical manifestation of any hepatic, renal, neurological, psychiatric, respiratory, endocrine, hematological, tumor, genitourinary, cardiovascular, gastrointestinal, musculoskeletal, dermatological (eg, contact dermatitis, atopic dermatitis), or other
- History of drug abuse or positive urine drug screen at screening
- For all female subjects, pregnant (Urine-HCG positive) or breast-feeding subjects
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Placebo
|
Experimental: LEM-S401
|
siRNA encapsulated in DegradaBALL®
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The safety and tolerability of LEM-S401 evaluated by incidence of adverse events
Time Frame: Up to 16 days
|
Evaluation of safety and tolerability of subcutaneous injections of LEM-S401.
Examination of any incidence of adverse events.
|
Up to 16 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Lemonex Inc. Study Director, Lemonex Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 11, 2022
Primary Completion (Actual)
October 18, 2022
Study Completion (Actual)
February 3, 2023
Study Registration Dates
First Submitted
January 11, 2021
First Submitted That Met QC Criteria
January 11, 2021
First Posted (Actual)
January 13, 2021
Study Record Updates
Last Update Posted (Estimate)
February 16, 2023
Last Update Submitted That Met QC Criteria
February 14, 2023
Last Verified
February 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- LEM-S401-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cicatrix
-
Samsung Medical CenterSeoul National University Hospital; Kyunghee University Medical Center; InovailUnknownHypertrophic CicatrixKorea, Republic of
-
Olix Pharmaceuticals, Inc.CompletedCicatrix, HypertrophicUnited Kingdom
-
HugelCompletedHypertrophic ScarKorea, Republic of
-
Hospital Universitari Vall d'Hebron Research InstituteCompletedCicatrix, HypertrophicSpain
-
SolitonUnited States Naval Medical Center, San DiegoNot yet recruitingScars, Hypertrophic
-
Seton Healthcare FamilyCompleted
-
Massachusetts General HospitalWithdrawnHypertrophic ScarsUnited States
-
University of California, Los AngelesWithdrawnCosmetics, Suture, CicatrixUnited States
-
Nova Scotia Health AuthorityRecruiting
-
Henry Ford Health SystemActive, not recruitingScar | Hypertrophic ScarUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States